Issue link: https://www.e-digitaleditions.com/i/1544305
Inhalation April 2026 37 Inhalation capabilities from discovery to delivery e 2025 Vectura acquisition has expanded capabili- ties at Phillips Medisize. Today, we specialize in inno- vative inhaled drug development, leveraging more than 25 years of experience to help bring your med- icines to market. Our combination of formulation science, device technology and inhaled development expertise has contributed to the success of 13 inhaled medicines launched by our partners and licensees. Our expertise spans small molecules, biologics, com- plex combinations and generic products for pMDI, DPI, nasal inhaler and nebulization devices. We invite you to explore more about our proven inhala- tion services. Phillips Medisize US: +1 715 232-0942 PMCInfo@molex.com www.phillipsmedisize.com Smart, breath-actuated mesh nebulizer HCmed is a CDMO that specializes in inhala- tion drug delivery systems. Leveraging proprietary vibrating mesh technology, we provide an integrated platform for developing drug-device combination products, offering customized solutions for pharma- ceutical partners. Our AdheResp is the first US FDA 510(k)-cleared breath-actuated mesh nebulizer with built-in connectivity and is ready for large-scale man- ufacturing to support clinical trials and accelerate new drug development. Its advanced design improves drug delivery efficiency and reduces fugitive aerosol emissions. From concept through commercialization, HCmed is a trusted partner for delivering innovative inhaled combination products to market. HCmed Innovations Co., Ltd. Taiwan: +886 2 2732 6596 info@hcmed-inno.com www.hcmed-inno.com Announcing an MDI coated-can patent In January of 2026, the European Patent office granted a patent for the first 100% PFAS-free, traditionally sprayed-coated MDI can. is product has been filled using 134a as well as both new-generation propellants, 1234ze and 152a, showing successful pharma results in all three cases. As deeper PFAS bans lurk, this prod- uct can provide a safe alternative for the inhalation industry as it seeks the lowest risk path. For more information, please contact Randy Churchill. Or visit us at our RDD 2026 booth or at biomerics.com. Biomerics US: +1 540 246-1930 rchurchill@biomerics.com www.biomerics.com. Role of excipients for respiratory delivery Building upon more than 20 years of experience, Lonza continues to drive research in formulation for inhaled delivery of biologics. Excipient choice in drug formulation plays a key role in this process, and when combining a large molecule with one or more excip- ients, factors such as their own properties, route of administration, dosage form and processing condi- tions need to be considered. With dedicated technol- ogies and facilities, Lonza's scientists are identifying new, leading approaches with excipients and provid- ing support for navigating the regulatory landscape. Lonza Small Molecules US: +1 813 286-0404 small.molecules@lonza.com www.lonza.com

